172 results on '"Campieri M"'
Search Results
2. The use of probiotics in inflammatory bowel disease
3. P.08.17 SINGLE VS DUAL-CAMERA: A COMPARATIVE ANALYSIS OF COLON CAPSULE ENDOSCOPY TO EVALUATE THE SMALL BOWEL
4. P.08.18 A NEW DEDICATED CAPSULE FOR DIAGNOSIS AND MONITORING OF CROHN'S DISEASE. FIRS PATIENT SERIES
5. P683 Maintenance of deep remission in patients with ulcerative colitis treated with thiopurines after withdrawal of the drug: Perspective real-life experience of a single centre
6. P269 A new dedicated capsule for diagnosis and monitoring of Crohn’s disease. First patient series
7. Stress and brain functional changes in patients with Crohn's disease: A functional magnetic resonance imaging study
8. P.06.23: Capsule Endoscopy – Accuracy and Prognostic Value of Small Bowel Lesions in Patients with Crohn’s Disease
9. P.11.19: Maintenance of Deep Remission in Patients with Ulcerative Colitis Treated with Thiopurines after Withdrawal of the Drug: Perspective Real-Life Experience of a Single Center
10. P581 Highly purified eicosapentaenoic acid, as free fatty acid, reduces fecal calprotectin levels and prevents clinical relapse in ulcerative colitis patients: a double-blind, randomized, placebo controlled trial
11. P571 Can Crohn's colits be cured by surgery?
12. Intestinal Transit time is Related with Different Anorectal Motility Patterns in Chronic Non-Organic Constipation
13. Antibiotics and probiotics
14. P370 Prospective withdrawal trial of azathioprine (AZA) in ulcerative colitis (UC)
15. OC.11.4 RE-GAIN OF RESPONSE IN CROHN'S DISEASE ADALIMUMAB (ADA) DOSE-ESCALATING FAILURE OR EARLY RELAPSE. A SINGLE CENTRE EXPERIENCE
16. P.08.2 THE LONG-TERM CLINICAL COURSE OF REFRACTORY CHRONIC POUCHITIS AFTER INFLIXIMAB THERAPY
17. P.01.2 ADALIMUMAB FOR THE TREATMENT OF POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE. A SINGLE CENTRE EXPERIENCE
18. P604 Adalimumab for the treatment of post-operative recurrence of Crohn's disease. A single centre experience
19. P395 Re-induction regimen in Crohn's disease adalimumab failure or disease relapse after a first adalimumab course. A single centre experience
20. Randomized Controlled Trials in Pouchitis
21. New insights into the brain involvement in patients with Crohn’s disease: a voxel‐based morphometry study
22. CS.02.3 ADALIMUMAB IN THE TREATMENT OF PERIANAL CROHN'S DISEASE: LONG TERM RESULTS IN A SINGLE TERTIARY CENTER
23. P.06.2 EFFICACY, SAFETY, IMPACT ON NATURAL HISTORY OF LONG-TERM TREATMENT WITH THIOPURINES IN CROHN'S DISEASE PATIENTS. A SINGLE CENTER EXPERIENCE
24. OC.06.2 LONG-TERM OUTCOME AFTER INFLIXIMAB TREATMENT FOR DISTAL REFRACTORY ULCERATIVE COLITIS. A SINGLE TERTIARY CENTER EXPERIENCE
25. P.05.8 ORAL BECLOMETHASONE DIPROPIONATE IN THE TREATMENT OF CHRONIC REFRACTORY POUCHITIS
26. P391 Risk of short-term postoperative complications in patients treated with azathioprine for Crohn's disease. A single center experience
27. P377 Long-term outcome after infliximab treatment for distal refractory ulcerative colitis. A single tertiary center experience
28. P393 Combination of surgical therapy and local injections of adalimumab in treatment of complex perianal Crohn's disease
29. P386 Long term functional results and quality of life after restorative proctocolectomy for ulcerative colitis: A twenty years experience
30. P361 Adalimumab in the treatment of perianal Crohn's disease: Long-term results in a single tertiary center
31. P002 The potential role of IL-33 in inflammatory-associated gut fibrosis: Induction of pro-fibrogenic gene expression and myofibroblast hypertrophy
32. P375 Efficacy, safety, impact on natural history of long-term treatment with thiopurines in Crohn's disease patients. A single center experience
33. P380 Oral beclomethasone dipropionate in the treatment of chronic refractory pouchitis
34. Distinct proteomic profiles characterise non-erosive from erosive reflux disease
35. PC.1.3: IL-33-DEPENDENT INDUCTION OF INTESTINAL PROFIBROTIC GENE EXPRESSION AND MYOFIBROBLAST HYPERTROPHY: POTENTIAL ROLE IN INFLAMMATORY-ASSOCIATED GUT FIBROSIS
36. P.1.23: CELL PROLIFERATION ACTIVITY OF OESOPHAGEAL SQUAMOUS EPITHELIUM IN ERD IS REDUCED COMPARED TO NERD
37. Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells
38. Potential role of the cannabinoid receptor CB1 in the pathogenesis of erosive and non‐erosive gastro‐oesophageal reflux disease
39. Adult Attachment and Early Parental Experiences in Patients With Crohn's Disease
40. P.70 ADALIMUMAB IN THE TREATMENT OF PERIANAL CROHN'S DISEASE: A SINGLE CENTER EXPERIENCE IN 64 PATIENTS
41. OC.01.8 USE OF INFLIXIMAB AND ADALIMUMAB IN REFRACTORY POUCHITIS
42. P.17 ROLE OF CB1 IN THE EROSIVE AND NON-EROSIVE GASTRO-ESOPHAGEAL REFLUX DISEASE
43. OC.07.1 ADALIMUMAB IS EFFECTIVE IN THE TREATMENT OF ACTIVE LUMINAL CROHN'S DISEASE AND MUCOSAL HEALING: A SINGLE CENTER EXPERIENCE IN 170 PATIENTS
44. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX®with Asacol®
45. PP33 ADALIMUMAB DOES NOT INFLUENCE PITUITARY ADENOMA IN A CHILD WITH ACTIVE REFRACTORY CROHN'S DISEASE
46. P155 - Efficacy of enemas containing combination of mesalazine and methyl-prednisolone in active distal refractory ulcerative colitis
47. P135 - Efficacy of infliximab in active refractory ulcerative colitis
48. P184 - Adalimumab in the treatment of active luminal and perianal Crohn's disease: a single center experience in 100 patients
49. Which therapies are advisable in pouchitis?
50. Which therapies are advisable in pouchitis?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.